Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

NCT04130542 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

276

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

BIOLOGICAL: LVGN6051
BIOLOGICAL: KEYTRUDA® (pembrolizumab)

Sponsor

Lyvgen Biopharma Holdings Limited

Collaborators

[object Object]